Combination Therapy of F16IL2 and Doxorubicin in Solid Tumour Patients

Model scores of the 29,894 trials active now.

Model score 20% for any early termination, 5% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 29% of the time (655 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2012-12-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cancerchemotherapytherapyradiationpatients must
  Phrases that lowered it: aminotransferaseseverehumanpharmacokineticinvestigator
• Phase: 1/2 (raises risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Trials the sponsor started in the prior 2 years: 2 (raises risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Has a data monitoring committee: No (lowers risk) · Design
• Number of arms: 1 (raises risk) · Design
• Disease area, dermatology: Yes (raises risk) · Disease area
• Drug's FAERS reports with a death: 21.3% (lowers risk) · Drug's FDA history
• Blinding: none (raises risk) · Design
• Sponsor's past trials: 0 (raises risk) · Sponsor's track record

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• L19TNFα in Combination With Doxorubicin in Patients With Advanced Solid Tumours NCT02076620 · started 2013 · scored riskier than 83% of active trials completed
• Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients NCT01134250 · started 2008 · scored riskier than 70% of active trials completed
• Phase 1 Trial of Intravenously Administered Nerofe™ in Subjects With Advanced Malignancies NCT01690741 · started 2013 · scored riskier than 46% of active trials completed
• A Phase 1 Clinical Trial of AUR106 in Patients With Relapsed Advanced Malignancies NCT05861947 · started 2023 · scored riskier than 42% of active trials terminated
• A Dose Finding and Efficacy Study of the Tumour Targeting Human 131I-F16SIP Monoclonal Antibody in Patients With Cancer NCT01240720 · started 2008 · scored riskier than 81% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.